CHRNA3 rs1051730 genotype and short-term smoking cessation

Nicotine and Tobacco Research

Volumn 13, Issue 10, 2011, Pages 982-988

  Munafò, Marcus R ^a   Johnstone, Elaine C ^b   Walther, Donna ^c   Uhl, George R ^c   Murphy, Michael F G ^b   Aveyard, Paul ^d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; COTININE; DNA; NICOTINE PATCH; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 3 SUBUNIT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SALIVA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE; TREATMENT DURATION; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ALLELES; CARBON MONOXIDE; COTININE; DNA; FOLLOW-UP STUDIES; GENETIC MARKERS; GENOTYPE; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MIDDLE AGED; MULTIGENE FAMILY; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NICOTINIC; SALIVA; SMOKING; TOBACCO USE CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053467776     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntr106     Document Type: Article

References (36)

1. Aveyard, P., Brown, K., Saunders, C., Alexander, A., Johnstone, E., Munafo, M. R., et al. (2007). Weekly versus basic smoking cessation support in primary care: A randomised controlled trial. Thorax, 62, 898-903. doi:10.1136/thx.2006.071837.
2. Baker, T. B., Weiss, R. B., Bolt, D., von Niederhausern, A., Fiore, M. C., Dunn, D. M., et al. (2009). Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine & Tobacco Research, 11, 785-796. doi:10.1093/ntr/ntp064.
3. Balfour, D. J. (2004). The neurobiology of tobacco dependence: A preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine & Tobacco Research, 6, 899-912. doi:10.1080/14622200412331324965.
4. Berrettini, W., Yuan, X., Tozzi, F., Song, K., Francks, C., Chilcoat, H., et al. (2008). Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Molecular Psychiatry, 13, 368-373. doi:10.1038/sj.mp.4002154.
5. Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Grucza, R. A., Xuei, X., et al. (2008). Variants in nicotinic receptors and risk for nicotine dependence. American Journal of Psychiatry, 165, 1163-1171. doi:10.1176/appi.ajp.2008.07111711.
6. Dahl, J. P., Jepson, C., Levenson, R., Wileyto, E. P., Patterson, F., Berrettini, W. H., et al. (2006). Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics Journal, 6, 194-199. doi:10.1038/sj.tpj.6500358.
7. David, S. P., Munafo, M. R., Murphy, M. F., Proctor, M., Walton, R. T., & Johnstone, E. C. (2008). Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: Follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics Journal, 8, 122-128. doi:10.1038/sj.tpj.6500447.
8. David, S. P., Munafo, M. R., Murphy, M. F., Walton, R. T., & Johnstone, E. C. (2007). The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. Nicotine & Tobacco Research, 9, 225-231. doi:10.1080/14622200601078566.
9. Freathy, R. M., Ring, S. M., Shields, B., Galobardes, B., Knight, B., Weedon, M. N., et al. (2009). A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Human Molecular Genetics, 18, 2922-2927. doi:10.1093/hmg/ddp216.
10. Hughes, J. R. (2003). Motivating and helping smokers to stop smoking. Journal of General Internal Medicine, 18, 1053-1057. doi:10.1111/j.1525-1497.2003.20640.x.
11. Hughes, J. R., Keely, J. P., Niaura, R. S., Ossip-Klein, D. J., Richmond, R. L., & Swan, G. E. (2003). Measures of abstinence in clinical trials: Issues and recommendations. Nicotine & Tobacco Research, 5, 13-25. doi:10.1080/14622200307270.
12. Imperial-Cancer-Research-Fund. (1993). Effectiveness of a nicotine patch in helping people stop smoking: Results of a randomised trial in general practice. British Medical Journal, 306, 1304-1308. doi:10.1136/bmj.306.6888.1304.
13. Jackson, K. J., Marks, M. J., Vann, R. E., Chen, X., Gamage, T. F., Warner, J. A., et al. (2010). Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. Journal of Pharmacology and Experimental Therapeutics, 334, 137-146. doi:10.1124/jpet.110.165738.
14. Johnstone, E. C., Elliot, K. M., David, S. P., Murphy, M. F., Walton, R. T., & Munafo, M. R. (2007). Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology Biomarkers and Prevention, 16, 1065-1069. doi:10.1158/1055-9965.EPI-06-0936.
15. Johnstone, E. C., Yudkin, P. L., Hey, K., Roberts, S. J., Welch, S. J., Murphy, M. F., et al. (2004). Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics, 14, 83-90. doi:10.1097/00008571-200402000-00002.
16. Lerman, C., Jepson, C., Wileyto, E. P., Epstein, L. H., Rukstalis, M., Patterson, F., et al. (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology, 31, 231-242. doi:10.1038/sj.npp.1300861.
17. Lerman, C., Tyndale, R., Patterson, F., Wileyto, E. P., Shields, P. G., Pinto, A., et al. (2006). Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology and Therapeutics, 79, 600-608. doi:10.1016/j.clpt.2006.02.006.
18. Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J., Restine, S., et al. (2004). The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics Journal, 4, 184-192. doi:10.1038/sj.tpj.6500238.
19. Liu, J. Z., Tozzi, F., Waterworth, D. M., Pillai, S. G., Muglia, P., Middleton, L., et al. (2010). Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nature Genetics, 42, 436-440. doi:10.1038/ng.572.
20. Malaiyandi, V., Lerman, C., Benowitz, N. L., Jepson, C., Patterson, F., & Tyndale, R. F. (2006). Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Molecular Psychiatry, 11, 400-409. doi:10.1038/sj.mp.4001794.
21. Munafo, M. R., Clark, T., Johnstone, E., Murphy, M., & Walton, R. (2004). The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine & Tobacco Research, 6, 583-597. doi:10.1080/14622200410001734030.
22. Munafo, M. R., & Flint, J. (2004). Meta-analysis of genetic association studies. Trends in Genetics, 20, 439-444. doi:10.1016/j.tig.2004.06.014.
23. Munafo, M. R., Johnstone, E. C., Wileyto, E. P., Shields, P. G., Elliot, K. M., & Lerman, C. (2006). Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiology Biomarkers and Prevention, 15, 398-400. doi:10.1158/1055-9965.EPI-05-0648.
24. Munafo, M. R., Shields, A. E., Berrettini, W. H., Patterson, F., & Lerman, C. (2005). Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics, 6, 211-223. doi:10.1517/14622416.6.3.211.
25. Phillips, A. N., & Smith, G. D. (1993). The design of prospective epidemiological studies: More subjects or better measurements? Journal of Clinical Epidemiology, 46, 1203-1211. doi:10.1016/0895-4356(93)90120-P.
26. Pontieri, F. E., Tanda, G., Orzi, F., & Di Chiara, G. (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382, 255-257. doi:10.1038/382255a0.
27. Saccone, S. F., Hinrichs, A. L., Saccone, N. L., Chase, G. A., Konvicka, K., Madden, P. A., et al. (2007). Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Human Molecular Genetics, 16, 36-49. doi:10.1093/hmg/ddl438.
28. Society-for-Research-on-Nicotine-and-Tobacco. (2002). Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research, 4, 149-159. doi:10.1080/14622200210123581.
29. Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., et al. (2008). A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature, 452, 638-642. doi:10.1038/nature06846.
30. Thorgeirsson, T. E., Gudbjartsson, D. F., Surakka, I., Vink, J. M., Amin, N., Geller, F., et al. (2010). Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nature Genetics, 42, 448-453. doi:10.1038/ng.573.
31. Thorgeirsson, T. E., & Stefansson, K. (2010). Commentary: Gene-environment interactions and smoking-related cancers. International Journal of Epidemiology, 39, 577-579. doi:10.1093/ije/dyp385.
32. Tobacco-and-Genetics-Consortium. (2010). Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nature Genetics, 42, 441-447. doi:10.1038/ng.571.
33. Uhl, G. R., Drgon, T., Johnson, C., Walther, D., David, S. P., Aveyard, P., et al. (2010). Genome-wide association for smoking cessation success: Participants in the Patch in Practice trial of nicotine replacement. Pharmacogenomics, 11, 357-367. doi:10.2217/pgs.09.156.
34. West, R., Hajek, P., Stead, L., & Stapleton, J. (2005). Outcome criteria in smoking cessation trials: Proposal for a common standard. Addiction, 100, 299-303. doi:10.1111/j.1360-0443.2004.00995.x.
35. Yudkin, P., Hey, K., Roberts, S., Welch, S., Murphy, M., & Walton, R. (2003). Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. British Medical Journal, 327, 28-29. doi:10.1136/bmj.327.7405.28.
36. Yudkin, P., Munafo, M., Hey, K., Roberts, S., Welch, S., Johnstone, E., et al. (2004). Effectiveness of nicotine patches in relation to genotype in women versus men: Randomised controlled trial. British Medical Journal, 328, 989-990. doi:10.1136/bmj.38050.674826.AE.